Notes
The study was sponsored by GlaxoSmithKline.
Reference
Stanford RH, et al. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA. Respiratory Medicine 150: 1-7, Apr 2019. Available from: URL: http://doi.org/10.1016/j.rmed.2019.01.019
Rights and permissions
About this article
Cite this article
Fluticasone furoate/vilanterol reduces exacerbation risk in COPD. PharmacoEcon Outcomes News 826, 14 (2019). https://doi.org/10.1007/s40274-019-5816-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5816-7